JP2025092589A5 - - Google Patents

Info

Publication number
JP2025092589A5
JP2025092589A5 JP2025053695A JP2025053695A JP2025092589A5 JP 2025092589 A5 JP2025092589 A5 JP 2025092589A5 JP 2025053695 A JP2025053695 A JP 2025053695A JP 2025053695 A JP2025053695 A JP 2025053695A JP 2025092589 A5 JP2025092589 A5 JP 2025092589A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025053695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025092589A (ja
Filing date
Publication date
Priority claimed from PCT/JP2021/009798 external-priority patent/WO2021182573A1/ja
Application filed filed Critical
Publication of JP2025092589A publication Critical patent/JP2025092589A/ja
Publication of JP2025092589A5 publication Critical patent/JP2025092589A5/ja
Pending legal-status Critical Current

Links

JP2025053695A 2020-03-12 2025-03-27 癌の治療及び/又は予防のための医薬品 Pending JP2025092589A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020043021 2020-03-12
JP2020043021 2020-03-12
PCT/JP2021/009798 WO2021182573A1 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品
JP2021532006A JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021532006A Division JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Publications (2)

Publication Number Publication Date
JP2025092589A JP2025092589A (ja) 2025-06-19
JP2025092589A5 true JP2025092589A5 (cg-RX-API-DMAC7.html) 2026-02-02

Family

ID=77671643

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532006A Active JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品
JP2025053695A Pending JP2025092589A (ja) 2020-03-12 2025-03-27 癌の治療及び/又は予防のための医薬品

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021532006A Active JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Country Status (7)

Country Link
US (1) US20230129035A1 (cg-RX-API-DMAC7.html)
EP (1) EP4119156A4 (cg-RX-API-DMAC7.html)
JP (2) JP7797875B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152318A (cg-RX-API-DMAC7.html)
BR (1) BR112022018157A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175137A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021182573A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2322221T3 (da) * 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022319362A1 (en) * 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240042415A (ko) * 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4378478A4 (en) * 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
JPWO2024043252A1 (cg-RX-API-DMAC7.html) * 2022-08-24 2024-02-29
AU2023329564A1 (en) * 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN119768181A (zh) * 2022-08-24 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品
AU2024236246A1 (en) * 2023-03-14 2025-10-30 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
KR101545914B1 (ko) 2009-09-22 2015-08-20 프로바이오겐 아게 특수화된 글리칸 구조를 함유하는 분자의 생산 방법
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
AU2011211699B2 (en) 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US20130108623A1 (en) 2010-03-29 2013-05-02 Zymeworks Inc Antibodies with Enhanced or Suppressed Effector Function
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01714A (cg-RX-API-DMAC7.html) 2012-02-21 2015-10-23 Toray Industries
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2018234879A1 (en) * 2017-06-22 2018-12-27 Novartis Ag USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
WO2019189780A1 (ja) 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び/又は予防用医薬組成物
JP7103097B2 (ja) 2018-09-13 2022-07-20 トヨタ自動車株式会社 燃料電池車両

Similar Documents

Publication Publication Date Title
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2022515487A5 (cg-RX-API-DMAC7.html)
US9994632B2 (en) Humanized or affinity-matured anti Ang-2 antibody and uses thereof
JP2019535250A5 (cg-RX-API-DMAC7.html)
JP2018508483A5 (cg-RX-API-DMAC7.html)
JP2013527762A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2020514310A5 (cg-RX-API-DMAC7.html)
JP2017514461A5 (cg-RX-API-DMAC7.html)
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
JP2018503365A5 (cg-RX-API-DMAC7.html)
JP2014530215A5 (cg-RX-API-DMAC7.html)
JP2021513540A5 (cg-RX-API-DMAC7.html)
JP2014158469A5 (cg-RX-API-DMAC7.html)
HRP20180262T1 (hr) Monoklonska anti-gt468 protutijela za liječenje karcinoma
JP2026041845A5 (cg-RX-API-DMAC7.html)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2021522347A5 (cg-RX-API-DMAC7.html)
JP2022512750A5 (cg-RX-API-DMAC7.html)
JP2024511137A5 (cg-RX-API-DMAC7.html)
CA3208455A1 (en) Novel anti-gremlin1 antibodies
JP2021533796A5 (cg-RX-API-DMAC7.html)
JP2024512574A5 (cg-RX-API-DMAC7.html)
JP2023545521A5 (cg-RX-API-DMAC7.html)
JP2025513745A5 (cg-RX-API-DMAC7.html)